Key result
CPUY11018 shortens AF duration in a rat model by blocking Ito and IKur currents.
Why the study?
Does CPUY11018 reduce atrial fibrillation duration in a rat model?
Does CPUY11018 reduce atrial fibrillation duration in a rat model?
The novel class III antiarrhythmic agent CPUY11018 shortens atrial fibrillation duration in a rat model by inhibiting specific potassium currents.
Hypothesis-generating for CPUY11018 in rat AF; leaves open clinical translation pending human trials.
CPUY11018 has anti‐atrial fibrillation (AF) effects in rats. The effects of CPUY11018 on the transient outward K + current ( I to ) and ultra‐rapid delayed rectifier K + current ( I Kur ) were studied using whole‐cell patch clamp techniques and an acetylcholine (ACh)‐CaCl 2 induced AF model. CPUY11018 inhibited I to and I Kur in a concentration‐dependent manner with IC 50 values of 18.5 and 1.7 µM, respectively. Inhibition was independent of the depolarizing voltage. In the AF ACh‐CaCl 2 model, AF duration was effectively shortened after treatment with 5 mg/kg CPUY11018 for 4 days. These results indicate that CPUY11018 is effective in treating AF partly by blocking I to and I Kur . Drug Dev Res 71, 2010.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2010) studied Atrial fibrillation. CPUY11018 was evaluated on Atrial fibrillation duration and inhibition of Ito and IKur. CPUY11018 effectively shortened atrial fibrillation duration in a rat model after 4 days of treatment at 5 mg/kg, partly by blocking Ito and IKur currents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: